Inoviq Ltd (AU:IIQ) has released an update.
INOVIQ Ltd has successfully exceeded its share purchase plan (SPP) target, raising A$9.379 million with strong shareholder support, leading to an oversubscription and a scaling back of applications. The funds will drive the commercialization of cancer diagnostics and therapeutics, including the EXO-NET research tools and SubB2M tests for breast and ovarian cancer. Shareholders participating in the SPP and recent placement were also granted options, boosting INOVIQ’s cash balance to A$14.489 million to advance its diagnostic and therapeutic pipeline.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
